ThislabelmaynotbethelatestapprovedbyFDA.
Forcurrentlabelinginformation,pleasevisit/drugsatfda
HIGHLIGHTSOFPRESCRIBINGINFORMATIONWARNINGSANDPRECAUTIONS
Thesehighlightsdonotincludealltheinformationneededtouse?ToxicitiesAssociatedwithInappropriateAdministration:Lifethreatening
YCANTHsafelyandeffectively.Seefullprescribinginformationfororfataltoxicitiescanoccurifadministeredorally.Avoidcontactwiththe
YCANTH.treatmentarea,includingoralcontact,aftertreatment.Oculartoxicitycan
occurifYCANTHcomesincontactwitheyes.IfYCANTHgetsineyes,
YCANTHTM(cantharidin)topicalsolutionflusheyeswithwaterforatleast15minutes.(5.1)
InitialU.S.Approval:YYYY?LocalSkinReactions:Reactionsattheapplicationsitehaveincluded
vesiculation,pruritus,pain,discoloration,anderythema.Avoidapplication
INDICATIONSANDUSAGEneareyesandmucosaltissue,andtohealthyskin.IfYCANTHcontacts
YCANTHisindicatedforthetopicaltreatmentofmolluscumcontagiosuminanyunintendedsurface,orhealthyskin,immediatelyremove.Ifsevere
adultandpediatricpatients2yearsofageandolder.(1)localskinreactionsoccur,removepriorto24hoursaftertreatment.(5.2)